Ken H Young | Scholars@Duke

Ken H Young
Professor of Pathology

I am a clinically-oriented diagnostic physician with clinical expertise in the pathologic diagnosis of hematologic cancers including tumors of the bone marrow, lymphoid tissue, spleen and pre-malignant hematologic conditions. Another area of interest is blood cancer classification with molecular and genetic profiling. In my research program, we focus on molecular mechanisms of tumor progression, cell-of-origin, biomarkers, and novel therapeutic strategies in lymphoma, myeloma and leukemia. In addition to patient care and translational research, medical education and scientific communication are also part of interest. Many residents, fellows, graduates and postdocs have worked and been trained in our program. We perform comprehensive clinical and research functions that include bone marrow, lymphoma pathology, clinical flow cytometry, cytogenetics, molecular diagnostics and outside services.

We provide diagnostic consultation services and relevant specialized testing for patients with various types of acute and chronic leukemia, lymphoma and benign hematologic disorders. I am specialized in the diagnosis of hematological disorders, including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, B and T-cell lymphomas, Hodgkin lymphoma, cutaneous and orbital lymphomas and benign bone marrow and lymph node disorders.

Current Research Interests

1. Molecular and Genetic Profiling in Aggressive Lymphoma
2. Pathologic and Molecular Classification of Lymphoma
3. Biomarker study and Risk Stratification in Lymphoma

Office Hours

Division of Hematopathology and Department of Pathology, Duke University School of Medicine, Duke University Medical Center and Cancer Institute, 40 Duke Medicine Circle, Room 265M, Box 3712, Duke South, Green Zone, Durham, NC 27710. Office Phone: 1-919-668-7568

Current Appointments & Affiliations

Professor of Pathology, Pathology, Clinical Science Departments 2019
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2019

Contact Information

1-919-668-7568, 40 Medicine Circle, Durham, NC 27710
40 Duke Medicine Circle, Box #3712 Duhs, Durham, NC 27710
ken.young@duke.edu (919) 668-7568

Background
Education, Training, & Certifications
- M.D., Zhejiang University (China) 1984
Medical Licensure
- NCMB2019. North Carolina. 2019
- TMB2010. Texas. 2010
Leadership & Clinical Positions at Duke
- - Professor, Department of Pathology, Clinical Science Department, 2019 - Current
  - Member, Duke Cancer Institute and Duke University Medical Center, 2019 - Current
  - Professor, tenured, Department of Hematopathology, University of Texas MD Anderson Cancer Center, 2016-2019
  - Associate Professor, Department of Hematopathology, University of Texas MD Anderson Cancer Center, 2010-2015
Academic Positions Outside Duke
- Professor with tenure, The University fo Texas MD Anderson Cancer Center. 2010 - 2019
Expertise
Subject Headings
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Huang, Xinxing, Ken H. Young, Wei Guo, Yinping Wang, Xueju Wang, Yanfeng Xi, Lifen Wang, and Ou Bai. “Identification of hepatitis B virus aetiologic antigens, HBx and Pre-S2, in diffuse large B-cell lymphoma.” J Viral Hepat 27, no. 9 (September 2020): 948–50. https://doi.org/10.1111/jvh.13301.
    Full Text Link to Item
  - Yang, Chunmei, Mixue Xie, Kaifeng Zhang, Hui Liu, Aibin Liang, Ken H. Young, and Wenbin Qian. “Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.” Leukemia, June 12, 2020. https://doi.org/10.1038/s41375-020-0913-y.
    Full Text Link to Item
  - Sobhani, Navid, Alberto D’Angelo, Xu Wang, Ken H. Young, Daniele Generali, and Yong Li. “Mutant p53 as an Antigen in Cancer Immunotherapy.” Int J Mol Sci 21, no. 11 (June 8, 2020). https://doi.org/10.3390/ijms21114087.
    Full Text Link to Item
  - Young, Ken H. “Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia.” Leukemia, May 12, 2020. https://doi.org/10.1038/s41375-020-0861-6.
    Full Text
  - Zhou, Hui, Zijun Y. Xu-Monette, Ling Xiao, Paolo Strati, Fredrick B. Hagemeister, Yizi He, Huan Chen, et al. “Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.” Blood Cancer J 10, no. 5 (May 4, 2020): 49. https://doi.org/10.1038/s41408-020-0312-7.
    Full Text Link to Item
  - Keane, Colm, Soi C. Law, Clare Gould, Simone Birch, Muhammed B. Sabdia, Lilia Merida de Long, Gayathri Thillaiyampalam, et al. “LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.” Blood Adv 4, no. 7 (April 14, 2020): 1367–77. https://doi.org/10.1182/bloodadvances.2019001390.
    Full Text Link to Item
  - Young, Ken H. “Hematopoietic stem cell transplantation for adults with T-cell lymphoblastic lymphoma: can we successfully step into the era of precision medicine?” Leukemia 34, no. 4 (April 2020): 1213–14. https://doi.org/10.1038/s41375-019-0608-4.
    Full Text Link to Item
  - Due, Hanne, Rasmus Froberg Brøndum, Ken H. Young, Martin Bøgsted, and Karen Dybkær. “MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.” Bmc Cancer 20, no. 1 (March 20, 2020): 237. https://doi.org/10.1186/s12885-020-6643-8.
    Full Text
  - You, Liangshun, Qingqing Lin, Jing Zhao, Fangjing Shi, Ken H. Young, and Wenbin Qian. “Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease.” Br J Haematol 188, no. 5 (March 2020): e64–67. https://doi.org/10.1111/bjh.16330.
    Full Text Link to Item
  - Shi, Ke, Qian Sun, Chun Qiao, Huayuan Zhu, Li Wang, Jiazhu Wu, Lili Wang, et al. “98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.” Cancer Med 9, no. 3 (February 2020): 999–1007. https://doi.org/10.1002/cam4.2788.
    Full Text Link to Item
  - Bao, Changqian, Xiandong Tao, Wei Cui, Bin Yi, Tiewen Pan, Ken H. Young, and Wenbin Qian. “SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients.” Exp Hematol Oncol 9 (2020): 16. https://doi.org/10.1186/s40164-020-00172-4.
    Full Text Link to Item
  - Deng, Qipan, Hui Hu, Xinfang Yu, Shuanglin Liu, Lei Wang, Weiqun Chen, Chi Zhang, et al. “Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant.” Nat Commun 10, no. 1 (November 7, 2019): 5061. https://doi.org/10.1038/s41467-019-13002-x.
    Full Text Link to Item
  - Xu-Monette, Zijun Y., Jianyong Li, Yi Xia, Beryl Crossley, Robert D. Bremel, Yi Miao, Min Xiao, et al. “Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.” J Immunother Cancer 7, no. 1 (October 22, 2019): 272. https://doi.org/10.1186/s40425-019-0730-x.
    Full Text Link to Item
  - Miao, Yi, L Jeffrey Medeiros, Yong Li, Jianyong Li, and Ken H. Young. “Genetic alterations and their clinical implications in DLBCL.” Nature Reviews Clinical Oncology 16, no. 10 (October 2019): 634–52. https://doi.org/10.1038/s41571-019-0225-1.
    Full Text Open Access Copy
  - Yu, Li, Tian-Tian Yu, and Ken H. Young. “Cross-talk between Myc and p53 in B-cell lymphomas.” Chronic Dis Transl Med 5, no. 3 (September 2019): 139–54. https://doi.org/10.1016/j.cdtm.2019.08.001.
    Full Text Link to Item
  - Wang, Lei, Qipan Deng, Hui Hu, Ming Liu, Zhaojian Gong, Shanshan Zhang, Zijun Y. Xu-Monette, et al. “Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice.” J Hematol Oncol 12, no. 1 (July 5, 2019): 70. https://doi.org/10.1186/s13045-019-0767-9.
    Full Text Link to Item
  - Li, Ling, Ruifang Sun, Yi Miao, Thai Tran, Lisa Adams, Nathan Roscoe, Bing Xu, et al. “PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.” Mod Pathol 32, no. 6 (June 2019): 741–54. https://doi.org/10.1038/s41379-018-0193-5.
    Full Text Open Access Copy Link to Item
  - Xu-Monette, Ziju Y., Min Xiao, Qingyan Au, Raghav Padmanabhan, Bing Xu, Nicholas Hoe, Sandra Rodríguez-Perales, et al. “Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.” Cancer Immunology Research 7, no. 4 (April 2019): 644–57. https://doi.org/10.1158/2326-6066.cir-18-0439.
    Full Text
  - Miao, Yi, L Jeffrey Medeiros, Zijun Y. Xu-Monette, Jianyong Li, and Ken H. Young. “Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.” Frontiers in Oncology 9 (January 2019): 107. https://doi.org/10.3389/fonc.2019.00107.
    Full Text Open Access Copy
  - Li, Li, Jun Zhang, Juan Chen, Zijun Y. Xu-Monette, Yi Miao, Min Xiao, Ken H. Young, et al. “B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.” Blood 132, no. 17 (October 2018): 1805–17. https://doi.org/10.1182/blood-2018-03-841015.
    Full Text
  - Wang, Xiaoxiao, Xin Cao, Ruifang Sun, Charlene Tang, Alexandar Tzankov, Jun Zhang, Ganiraju C. Manyam, et al. “Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.” Neoplasia (New York, N.Y.) 20, no. 6 (June 2018): 574–93. https://doi.org/10.1016/j.neo.2018.03.002.
    Full Text
  - García-Barchino, Maria J., Maria E. Sarasquete, Carlos Panizo, Julie Morscio, Antonio Martinez, Miguel Alcoceba, Vicente Fresquet, et al. “Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.” J Pathol 245, no. 1 (May 2018): 61–73. https://doi.org/10.1002/path.5060.
    Full Text Link to Item
  - Jain, N., H. Zhu, T. Khashab, Q. Ye, B. George, R. Mathur, R. K. Singh, et al. “Targeting nucleolin for better survival in diffuse large B-cell lymphoma.” Leukemia 32, no. 3 (March 2018): 663–74. https://doi.org/10.1038/leu.2017.215.
    Full Text Link to Item
  - Yao, Z., L. Deng, Z. Y. Xu-Monette, G. C. Manyam, P. Jain, A. Tzankov, C. Visco, et al. “Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.” Leukemia 32, no. 2 (February 2018): 353–63. https://doi.org/10.1038/leu.2017.222.
    Full Text
  - Wu, Huanling, L Jeffrey Medeiros, and Ken H. Young. “Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.” Blood Reviews 32, no. 1 (January 2018): 8–28. https://doi.org/10.1016/j.blre.2017.08.004.
    Full Text Open Access Copy
  - Xu-Monette, Zijun Y., Jianfeng Zhou, and Ken H. Young. “PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.” Blood 131, no. 1 (January 2018): 68–83. https://doi.org/10.1182/blood-2017-07-740993.
    Full Text Open Access Copy
  - Visco, Carlo, Jinfen Wang, Maria Chiara Tisi, Lijuan Deng, Emanuele S. G. D’Amore, Alexandar Tzankov, Santiago Montes-Moreno, et al. “Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.” Br J Cancer 117, no. 11 (November 21, 2017): 1685–88. https://doi.org/10.1038/bjc.2017.345.
    Full Text Link to Item
  - Li, Xin, Zijun Y. Xu-Monette, Shuhua Yi, Bouthaina S. Dabaja, Ganiraju C. Manyam, Jason Westin, Nathan Fowler, et al. “Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.” Am J Surg Pathol 41, no. 10 (October 2017): 1309–21. https://doi.org/10.1097/PAS.0000000000000923.
    Full Text Link to Item
  - Wang, Jinfen, Zijun Y. Xu-Monette, Kausar J. Jabbar, Qi Shen, Ganiraju C. Manyam, Alexandar Tzankov, Carlo Visco, et al. “AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.” The American Journal of Pathology 187, no. 8 (August 2017): 1700–1716. https://doi.org/10.1016/j.ajpath.2017.04.009.
    Full Text
  - Cai, Qingqing, Meifeng Tu, Zijun Y. Xu-Monette, Ruifang Sun, Ganiraju C. Manyam, Xiaolu Xu, Alexander Tzankov, et al. “NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.” Mod Pathol 30, no. 6 (June 2017): 854–76. https://doi.org/10.1038/modpathol.2017.5.
    Full Text Link to Item
  - Xia, Y., Z. Y. Xu-Monette, A. Tzankov, X. Li, G. C. Manyam, V. Murty, G. Bhagat, et al. “Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.” Leukemia 31, no. 3 (March 2017): 625–36. https://doi.org/10.1038/leu.2016.243.
    Full Text Open Access Copy Link to Item
  - Yu, Li, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, et al. “Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.” Blood 129, no. 12 (March 2017): 1658–68. https://doi.org/10.1182/blood-2016-11-748855.
    Full Text Open Access Copy
  - Xu-Monette, Zijun Y., Mingzhi Zhang, Jianyong Li, and Ken H. Young. “PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?” Frontiers in Immunology 8 (January 2017): 1597. https://doi.org/10.3389/fimmu.2017.01597.
    Full Text
  - Xu-Monette, Zijun Y., Ling Li, John C. Byrd, Kausar J. Jabbar, Ganiraju C. Manyam, Charlotte Maria de Winde, Michiel van den Brand, et al. “Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.” Blood 128, no. 26 (December 29, 2016): 3083–3100. https://doi.org/10.1182/blood-2016-05715094.
    Full Text Open Access Copy Link to Item
  - Pham, Lan V., Jerry L. Bryant, Richard Mendez, Juan Chen, Archito T. Tamayo, Zijun Y. Xu-Monette, Ken H. Young, et al. “Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.” Oncotarget 7, no. 49 (December 6, 2016): 80599–611. https://doi.org/10.18632/oncotarget.12413.
    Full Text Link to Item
  - Loghavi, Sanam, Sa A. Wang, L Jeffrey Medeiros, Jeffrey L. Jorgensen, Xin Li, Zijun Y. Xu-Monette, Roberto N. Miranda, and Ken H. Young. “Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology.” Leuk Lymphoma 57, no. 12 (December 2016): 2804–12. https://doi.org/10.3109/10428194.2016.1170827.
    Full Text Link to Item
  - Mai, Yun, J Jessica Yu, Boris Bartholdy, Zijun Y. Xu-Monette, Esther E. Knapp, Fei Yuan, Hongshan Chen, et al. “An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.” Blood 128, no. 24 (December 2016): 2797–2807. https://doi.org/10.1182/blood-2016-03-705814.
    Full Text
  - Xu-Monette, Zijun Y., Ling Li, John C. Byrd, Kausar J. Jabbar, Ganiraju C. Manyam, Charlotte Maria de Winde, Michiel van den Brand, et al. “Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.” Blood 128, no. 26 (December 2016): 3083–3100. https://doi.org/10.1182/blood-2016-05-715094.
    Full Text
  - Zhang, Mingzhi, Zijun Y. Xu-Monette, Ling Li, Ganiraju C. Manyam, Carlo Visco, Alexandar Tzankov, Jing Wang, et al. “RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.” Aging 8, no. 12 (December 2016): 3321–40. https://doi.org/10.18632/aging.101121.
    Full Text
  - Xu-Monette, Zijun Y., Qipan Deng, Ganiraju C. Manyam, Alexander Tzankov, Ling Li, Yi Xia, Xiao-Xiao Wang, et al. “Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.” Clin Cancer Res 22, no. 14 (July 15, 2016): 3593–3605. https://doi.org/10.1158/1078-0432.CCR-15-2296.
    Full Text Link to Item
  - Cao, Xin, L Jeffrey Medeiros, Yi Xia, Xiaoxiao Wang, Sheeba K. Thomas, Sanam Loghavi, Xin Li, et al. “Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.” Leuk Lymphoma 57, no. 5 (May 2016): 1104–13. https://doi.org/10.3109/10428194.2015.1096357.
    Full Text Link to Item
  - Batlle-López, Ana, Sonia González de Villambrosía, Mazorra Francisco, Sefora Malatxeberria, Anabel Sáez, Carlos Montalban, Lydia Sánchez, et al. “Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.” Oncotarget 7, no. 14 (April 5, 2016): 18036–49. https://doi.org/10.18632/oncotarget.7495.
    Full Text Link to Item
  - Kanagal-Shamanna, Rashmi, Zijun Y. Xu-Monette, Roberto N. Miranda, Ahmet Dogan, Dehui Zou, Rajyalakshmi Luthra, Donna M. Weber, et al. “Crystal-storing histiocytosis: a clinicopathological study of 13 cases.” Histopathology 68, no. 4 (March 2016): 482–91. https://doi.org/10.1111/his.12768.
    Full Text
  - Deng, L., Z. Y. Xu-Monette, S. Loghavi, G. C. Manyam, Y. Xia, C. Visco, J. Huh, et al. “Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.” Leukemia 30, no. 2 (February 2016): 361–72. https://doi.org/10.1038/leu.2015.237.
    Full Text
  - Winde, Charlotte M. de, Sharon Veenbergen, Ken H. Young, Zijun Y. Xu-Monette, Xiao-Xiao Wang, Yi Xia, Kausar J. Jabbar, et al. “Tetraspanin CD37 protects against the development of B cell lymphoma.” J Clin Invest 126, no. 2 (February 2016): 653–66. https://doi.org/10.1172/JCI81041.
    Full Text Link to Item
  - Xu-Monette, Zijun Y., Shanxiang Zhang, Xin Li, Ganiraju C. Manyam, Xiao-Xiao Wang, Yi Xia, Carlo Visco, et al. “p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.” Aging 8, no. 2 (February 2016): 345–65. https://doi.org/10.18632/aging.100898.
    Full Text
  - Ye, Qing, Zijun Y. Xu-Monette, Alexandar Tzankov, Lijuan Deng, Xiaoxiao Wang, Ganiraju C. Manyam, Carlo Visco, et al. “Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.” Oncotarget 7, no. 3 (January 2016): 2401–16. https://doi.org/10.18632/oncotarget.6262.
    Full Text
  - Xu-Monette, Zijun Y., Bouthaina S. Dabaja, Xiaoxiao Wang, Meifeng Tu, Ganiraju C. Manyam, Alexander Tzankov, Yi Xia, et al. “Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 28, no. 12 (December 2015): 1555–73. https://doi.org/10.1038/modpathol.2015.118.
    Full Text
  - Gordon, Michael W., Fang Yan, Xiaoming Zhong, Pranab Behari Mazumder, Zijun Y. Xu-Monette, Dehui Zou, Ken H. Young, Kenneth S. Ramos, and Yong Li. “Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma.” Molecular Carcinogenesis 54, no. 10 (October 2015): 1060–69. https://doi.org/10.1002/mc.22175.
    Full Text
  - Liu, Zhiyu, Zijun Y. Xu-Monette, Xin Cao, Ganiraju C. Manyam, Xiaoxiao Wang, Alexandar Tzankov, Yi Xia, et al. “Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 28, no. 10 (October 2015): 1297–1314. https://doi.org/10.1038/modpathol.2015.94.
    Full Text
  - Li, Ling, Zijun Y. Xu-Monette, Chi Young Ok, Alexandar Tzankov, Ganiraju C. Manyam, Ruifang Sun, Carlo Visco, et al. “Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.” Oncotarget 6, no. 27 (September 15, 2015): 23157–80. https://doi.org/10.18632/oncotarget.4319.
    Full Text Link to Item
  - Brauner, S., W. Zhou, C. Backlin, T. M. Green, L. Folkersen, M. Ivanchenko, B. Löfström, et al. “Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.” J Intern Med 278, no. 3 (September 2015): 323–32. https://doi.org/10.1111/joim.12375.
    Full Text Link to Item
  - Ok, Chi Young, Zijun Y. Xu-Monette, Ling Li, Ganiraju C. Manyam, Santiago Montes-Moreno, Alexandar Tzankov, Carlo Visco, et al. “Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 28, no. 9 (September 2015): 1202–13. https://doi.org/10.1038/modpathol.2015.76.
    Full Text
  - Cao, Xin, Qing Ye, Robert Z. Orlowski, Xiaoxiao Wang, Sanam Loghavi, Meifeng Tu, Sheeba K. Thomas, et al. “Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis.” J Hematol Oncol 8 (June 24, 2015): 74. https://doi.org/10.1186/s13045-015-0172-y.
    Full Text Link to Item
  - Ok, Chi Young, Qing Ye, Ling Li, Ganiraju C. Manyam, Lijuan Deng, Rashmi R. Goswami, Xiaoxiao Wang, et al. “Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?” Oncotarget 6, no. 16 (June 10, 2015): 13933–45. https://doi.org/10.18632/oncotarget.4324.
    Full Text Link to Item
  - Xu-Monette, Zijun Y., Meifeng Tu, Kausar J. Jabbar, Xin Cao, Alexandar Tzankov, Carlo Visco, Lalitha Nagarajan, et al. “Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.” Oncotarget 6, no. 16 (June 2015): 14720. https://doi.org/10.18632/oncotarget.4464.
    Full Text
  - Ma, Xiaodong, Daniel J. Conklin, Fenge Li, Zhongping Dai, Xiang Hua, Yan Li, Zijun Y. Xu-Monette, et al. “The oncogenic microRNA miR-21 promotes regulated necrosis in mice.” Nature Communications 6 (May 20, 2015): 7151. https://doi.org/10.1038/ncomms8151.
    Full Text
  - Dybkær, Karen, Martin Bøgsted, Steffen Falgreen, Julie S. Bødker, Malene K. Kjeldsen, Alexander Schmitz, Anders E. Bilgrau, et al. “Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.” J Clin Oncol 33, no. 12 (April 20, 2015): 1379–88. https://doi.org/10.1200/JCO.2014.57.7080.
    Full Text Link to Item
  - Falgreen, Steffen, Karen Dybkær, Ken H. Young, Zijun Y. Xu-Monette, Tarec C. El-Galaly, Maria Bach Laursen, Julie S. Bødker, et al. “Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.” Bmc Cancer 15 (April 8, 2015): 235. https://doi.org/10.1186/s12885-015-1237-6.
    Full Text Link to Item
  - Chen, Jiayu, Zijun Y. Xu-Monette, Lijuan Deng, Qi Shen, Ganiraju C. Manyam, Azahara Martinez-Lopez, Li Zhang, et al. “Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.” Oncotarget 6, no. 8 (March 20, 2015): 5597–5614. https://doi.org/10.18632/oncotarget.3343.
    Full Text Link to Item
  - Xu-Monette, Zijun Y., Meifeng Tu, Kausar J. Jabbar, Xin Cao, Alexandar Tzankov, Carol Visco, Lalitha Nagarajan, et al. “Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.” Oncotarget 6, no. 8 (March 2015): 5615–33. https://doi.org/10.18632/oncotarget.3479.
    Full Text
  - Liu, Ju, C. Zhang, X. L. Wang, P. Ly, V. Belyi, Z. Y. Xu-Monette, K. H. Young, W. Hu, and Z. Feng. “E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis.” Cell Death and Differentiation 21, no. 11 (November 2014): 1792–1804. https://doi.org/10.1038/cdd.2014.121.
    Full Text
  - Yu, Haiyang, Xuetian Yue, Yuhan Zhao, Xiaoyan Li, Lihua Wu, Cen Zhang, Zhen Liu, et al. “LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers.” Nature Communications 5 (October 17, 2014): 5218. https://doi.org/10.1038/ncomms6218.
    Full Text
  - Ok, Chi Young, Jiayu Chen, Zijun Y. Xu-Monette, Alexandar Tzankov, Ganiraju C. Manyam, Ling Li, Carlo Visco, et al. “Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.” Clin Cancer Res 20, no. 19 (October 1, 2014): 5113–23. https://doi.org/10.1158/1078-0432.CCR-14-0683.
    Full Text Link to Item
  - Wang, Shi, L Jeffrey Medeiros, Zijun Y. Xu-Monette, Shanxiang Zhang, Dennis P. O’Malley, Attilio Orazi, Zhuang Zuo, et al. “Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma.” Ann Diagn Pathol 18, no. 4 (August 2014): 203–9. https://doi.org/10.1016/j.anndiagpath.2014.03.007.
    Full Text Link to Item
  - Tzankov, Alexandar, Zijun Y. Xu-Monette, Marc Gerhard, Carlo Visco, Stephan Dirnhofer, Nora Gisin, Karen Dybkaer, et al. “Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.” Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc 27, no. 7 (July 2014): 958–71. https://doi.org/10.1038/modpathol.2013.214.
    Full Text
  - Ok, Chi Young, Zijun Y. Xu-Monette, Alexandar Tzankov, Dennis P. O’Malley, Santiago Montes-Moreno, Carlo Visco, Michael B. Møller, et al. “Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.” Cancer 120, no. 12 (June 2014): 1818–29. https://doi.org/10.1002/cncr.28664.
    Full Text
  - Ok, Chi Young, Ling Li, Zijun Y. Xu-Monette, Carlo Visco, Alexander Tzankov, Ganiraju C. Manyam, Santiago Montes-Moreno, et al. “Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 20, no. 9 (May 2014): 2338–49. https://doi.org/10.1158/1078-0432.ccr-13-3157.
    Full Text
  - Miranda, Roberto N., Tariq N. Aladily, H Miles Prince, Rashmi Kanagal-Shamanna, Daphne de Jong, Luis E. Fayad, Mitual B. Amin, et al. “Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 32, no. 2 (January 2014): 114–20. https://doi.org/10.1200/jco.2013.52.7911.
    Full Text
  - Wang, Shi, Alexander Tzankov, Zijun Y. Xu-Monette, Sylvia Hoeller, Sa A. Wang, Kristy L. Richards, Shanxiang Zhang, Jonathan W. Said, L Jeffrey Medeiros, and Ken H. Young. “Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications.” Human Pathology 44, no. 12 (December 2013): 2658–67. https://doi.org/10.1016/j.humpath.2013.07.007.
    Full Text
  - Frei, E., C. Visco, Z. Y. Xu-Monette, S. Dirnhofer, K. Dybkær, A. Orazi, G. Bhagat, et al. “Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.” J Clin Pathol 66, no. 11 (November 2013): 956–61. https://doi.org/10.1136/jclinpath-2013-201619.
    Full Text Link to Item
  - Chou, Feng-Pai, Ya-Wen Chen, Xianfeng F. Zhao, Zijun Y. Xu-Monette, Ken H. Young, Ronald B. Gartenhaus, Jehng-Kang Wang, et al. “Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.” The American Journal of Pathology 183, no. 4 (October 2013): 1306–17. https://doi.org/10.1016/j.ajpath.2013.06.024.
    Full Text
  - Jain, Preetesh, Xiuning Le, Ken H. Young, Keyur P. Patel, Sa Wang, Lin Pei, Lynne L. Barron, Lynne Abruzzo, and Susan O’Brien. “Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma.” Clinical Lymphoma, Myeloma & Leukemia 13, no. 5 (October 2013): 606–9. https://doi.org/10.1016/j.clml.2013.04.007.
    Full Text
  - Xu-Monette, Zijun Y., Michael B. Møller, Alexander Tzankov, Santiago Montes-Moreno, Wenwei Hu, Ganiraju C. Manyam, Louise Kristensen, et al. “MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.” Blood 122, no. 15 (October 2013): 2630–40. https://doi.org/10.1182/blood-2012-12-473702.
    Full Text Open Access Copy
  - Jain, Preetesh, Luis E. Fayad, Andreas Rosenwald, Ken H. Young, and Susan O’Brien. “Recent advances in de novo CD5+ diffuse large B cell lymphoma.” Am J Hematol 88, no. 9 (September 2013): 798–802. https://doi.org/10.1002/ajh.23467.
    Full Text Link to Item
  - Hu, Shimin, Zijun Y. Xu-Monette, Alexander Tzankov, Tina Green, Lin Wu, Aarthi Balasubramanyam, Wei-min Liu, et al. “MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.” Blood 121, no. 20 (May 16, 2013): 4021–31. https://doi.org/10.1182/blood-2012-10-460063.
    Full Text Open Access Copy Link to Item
  - Li, Yong, Michael W. Gordon, Zijun Y. Xu-Monette, Carlo Visco, Alexander Tzankov, Dehui Zou, Lugui Qiu, et al. “Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.” Blood 121, no. 22 (May 2013): 4529–40. https://doi.org/10.1182/blood-2012-12-471722.
    Full Text
  - Hu, Shimin, Zijun Y. Xu-Monette, Aarthi Balasubramanyam, Ganiraju C. Manyam, Carlo Visco, Alexander Tzankov, Wei-min Liu, et al. “CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.” Blood 121, no. 14 (April 4, 2013): 2715–24. https://doi.org/10.1182/blood-2012-10-461848.
    Full Text Open Access Copy Link to Item
  - Visco, Carlo, Alexander Tzankov, Zijun Y. Xu-Monette, Roberto N. Miranda, Yu Chuan Tai, Yan Li, Wei-min Liu, et al. “Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.” Haematologica 98, no. 2 (February 2013): 255–63. https://doi.org/10.3324/haematol.2012.066209.
    Full Text Link to Item
  - Hoeller, Sylvia, Yi Zhou, Rashmi Kanagal-Shamanna, Zijun Y. Xu-Monette, Daniela Hoehn, Michel Bihl, Steven H. Swerdlow, et al. “Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.” Human Pathology 44, no. 1 (January 2013): 110–21. https://doi.org/10.1016/j.humpath.2012.04.022.
    Full Text
  - Xu-Monette, Zijun Y., Lin Wu, Carlo Visco, Yu Chuan Tai, Alexander Tzankov, Wei-min Liu, Santiago Montes-Moreno, et al. “Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.” Blood 120, no. 19 (November 2012): 3986–96. https://doi.org/10.1182/blood-2012-05-433334.
    Full Text Open Access Copy
  - Green, Tina Marie, Ken H. Young, Carlo Visco, Zijun Y. Xu-Monette, Attilio Orazi, Ronald S. Go, Ole Nielsen, et al. “Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 28 (October 2012): 3460–67. https://doi.org/10.1200/jco.2011.41.4342.
    Full Text Open Access Copy
  - Visco, C., Y. Li, Z. Y. Xu-Monette, R. N. Miranda, T. M. Green, A. Tzankov, W. Wen, et al. “Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.” Leukemia 26, no. 9 (September 2012): 2103–13. https://doi.org/10.1038/leu.2012.83.
    Full Text Open Access Copy
  - Xu-Monette, Zijun Y., and Ken H. Young. “The TP53 tumor suppressor and autophagy in malignant lymphoma.” Autophagy 8, no. 5 (May 1, 2012): 842–45. https://doi.org/10.4161/auto.19703.
    Full Text Link to Item
  - Xu-Monette, Zijun Y., L Jeffrey Medeiros, Yong Li, Robert Z. Orlowski, Michael Andreeff, Carlos E. Bueso-Ramos, Timothy C. Greiner, Timothy J. McDonnell, and Ken H. Young. “Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.” Blood 119, no. 16 (April 19, 2012): 3668–83. https://doi.org/10.1182/blood-2011-11-366062.
    Full Text Link to Item
  - Green, Tina Marie, Ole Nielsen, Karin de Stricker, Zijun Y. Xu-Monette, Ken H. Young, and Michael Boe Møller. “High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.” Am J Surg Pathol 36, no. 4 (April 2012): 612–19. https://doi.org/10.1097/PAS.0b013e318244e2ba.
    Full Text Link to Item
  - Montes-Moreno, Santiago, Nerea Martinez, Beatriz Sanchez-Espiridión, Ramon Díaz Uriarte, Maria Elena Rodriguez, Anabel Saez, Carlos Montalbán, et al. “miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.” Blood 118, no. 4 (July 28, 2011): 1034–40. https://doi.org/10.1182/blood-2010-11-321554.
    Full Text Link to Item
  - Rossi, Davide, Valeria Spina, Clara Deambrogi, Silvia Rasi, Luca Laurenti, Kostas Stamatopoulos, Luca Arcaini, et al. “The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.” Blood 117, no. 12 (March 2011): 3391–3401. https://doi.org/10.1182/blood-2010-09-302174.
    Full Text
  - Rasi, Silvia, Valeria Spina, Alessio Bruscaggin, Tiziana Vaisitti, Claudio Tripodo, Francesco Forconi, Lorenzo De Paoli, et al. “A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.” Br J Haematol 152, no. 3 (February 2011): 284–94. https://doi.org/10.1111/j.1365-2141.2010.08482.x.
    Full Text Link to Item
  - Visco, Carlo, Sylvia Hoeller, Jeffrey T. Malik, Zijun Y. Xu-Monette, Michele L. Wiggins, Jessica Liu, Warren G. Sanger, et al. “Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component.” Am J Surg Pathol 35, no. 2 (February 2011): 177–89. https://doi.org/10.1097/PAS.0b013e3182049a9c.
    Full Text Open Access Copy Link to Item
- Conference Papers
  - Rassidakis, George, Yi Miao, Jun Zhang, Vassilis Atsaves, Lorand Kis, Karin E. Smedby, Yong Li, Zijun Yidan Xu-Monette, and Ken H. Young. “PD-L1 Expression and Gene Amplification in CD30+Diffuse Large B-Cell Lymphoma (DLBCL): Significance of TP53 Genetic Impact and Clinicopathologic Characteristics.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - Xu-Monette, Zijun Yidan, Li Yu, Tran Thai, Lisa Adams, Nathan Roscoe, Ganiraju Manyam, Carlo Visco, et al. “Clinical Significance of PD-1 and PD-L1 Expression and Ongoing Interaction in the Tumor Microenvironment in Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP.” In Blood, Vol. 130. AMER SOC HEMATOLOGY, 2017.
    Link to Item
  - Xu-Monette, Zijun Y., and Ken H. Young. “Abstract 666: CD37 tetraspanin as a novel biomarker for PD-1 blockade in diffuse large B-cell lymphoma.” In Clinical Research (Excluding Clinical Trials). American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-7445.am2017-666.
    Full Text
  - Reinholz, Monica Madden, Debrah Thompson, Ihab Botros, Paul Sportmann, Qian Liu, Pat Roche, Zijun Xu-Monette, Ken H. Young, and Bonnie LaFleur. “Next generation sequencing for DLBCL classification.” In Journal of Clinical Oncology, 34:11559–11559. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.11559.
    Full Text
  - Khouri, Issa F., Rima M. Saliba, Zijun Y. Xu-Monette, Gabriela Rondon, Rosamar Valverde, Martin Korbling, Alison M. Gulbis, et al. “Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT).” In Blood, 122:3350–3350. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.3350.3350.
    Full Text
  - Ok, Chi Young, Zijun Y. Xu-Monette, Alexander Tzankov, Carlo Visco, Santiago M. Montes, Karen Dybkaer, April Chiu, et al. “STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report Fro The International DLBCL Rituximab-CHOP Consortium Program.” In Blood, Vol. 122. AMER SOC HEMATOLOGY, 2013.
    Link to Item
  - Xu-Monette, Zijun Y., Alexander Tzankov, Yong Li, Carlo Visco, Santiago Montes-Moreno, Karen Dybkaer, April Chiu, et al. “MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program.” In Blood, Vol. 122. AMER SOC HEMATOLOGY, 2013.
    Link to Item
  - Xu-Monette, Zijun Y., Bouthaina S. Dabaja, Alexander Tzankov, Carlo Visco, Roberto N. Miranda, Karen Dybkaer, April Chiu, et al. “Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program.” In Blood, 122:213–213. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.213.213.
    Full Text
  - Zhou, Y., R. Kanagal-Shamanna, S. Hoeller, A. Tzankov, D. Hoehn, S. H. Swerdlow, A. Rosenwald, et al. “Molecular Characteristics of Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” In Laboratory Investigation, 92:385A-385A. NATURE PUBLISHING GROUP, 2012.
    Link to Item
  - Zhou, Y., R. Kanagal-Shamanna, S. Hoeller, A. Tzankov, D. Hoehn, S. H. Swerdlow, A. Rosenwald, et al. “Molecular Characteristics of Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.” In Modern Pathology, 25:385A-385A. NATURE PUBLISHING GROUP, 2012.
    Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Medical Licensure

Leadership & Clinical Positions at Duke

Academic Positions Outside Duke

Subject Headings

Selected Publications

Academic Articles

Conference Papers